Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
Adequate balance sheet and fair value.
Share Price & News
How has Alkermes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8AK has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 8AK underperformed the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: 8AK underperformed the German Market which returned 6.5% over the past year.
Price Volatility Vs. Market
How volatile is Alkermes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Alkermes undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 8AK (€18.5) is trading below our estimate of fair value (€32.3)
Significantly Below Fair Value: 8AK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 8AK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 8AK is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8AK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8AK is good value based on its PB Ratio (2.9x) compared to the DE Biotechs industry average (3.2x).
How is Alkermes forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8AK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8AK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8AK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 8AK's revenue (4.9% per year) is forecast to grow slower than the German market (5.1% per year).
High Growth Revenue: 8AK's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8AK's Return on Equity is forecast to be high in 3 years time (20.5%)
How has Alkermes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8AK is currently unprofitable.
Growing Profit Margin: 8AK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 8AK is unprofitable, and losses have increased over the past 5 years at a rate of -6.3% per year.
Accelerating Growth: Unable to compare 8AK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8AK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 8AK has a negative Return on Equity (-18.11%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Alkermes's financial position?
Financial Position Analysis
Short Term Liabilities: 8AK's short term assets ($962.0M) exceed its short term liabilities ($391.1M).
Long Term Liabilities: 8AK's short term assets ($962.0M) exceed its long term liabilities ($328.8M).
Debt to Equity History and Analysis
Debt Level: 8AK's debt to equity ratio (25.5%) is considered satisfactory.
Reducing Debt: 8AK's debt to equity ratio has increased from 25.5% to 25.5% over the past 5 years.
Inventory Level: 8AK has a high level of physical assets or inventory.
Debt Coverage by Assets: 8AK's debt is covered by short term assets (assets are 3.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8AK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 8AK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Alkermes's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 8AK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 8AK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8AK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8AK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8AK's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Pops (57yo)
Mr. Richard F. Pops has been the Chief Executive Officer of Alkermes PLC since September 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc. He was a Co-founder of Sirtris Pharmaceuticals, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD17.06M) is above average for companies of similar size in the German market ($USD2.69M).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||8.4yrs||US$17.06m||0.47% $14.0m|
|Senior VP & CFO||8.4yrs||US$3.62m||0.14% $4.1m|
|Senior VP||3.8yrs||US$3.60m||0.036% $1.1m|
|Executive VP of Research & Development and Chief Medical Officer||2.8yrs||US$3.79m||0.0088% $259.8k|
|Senior VP of Finance & Chief Accounting Officer||4.8yrs||no data||0.023% $688.9k|
|Co-Head of Investor Relations||0yrs||no data||no data|
|Vice President of Product & R&D Communications||0yrs||no data||no data|
|Senior VP of Corporate Development & Chief Risk Officer||8.4yrs||US$1.36m||0.13% $3.7m|
|Senior VP of Sales & Marketing||0.8yrs||no data||no data|
Experienced Management: 8AK's management team is considered experienced (4.8 years average tenure).
|Chairman & CEO||8.4yrs||US$17.06m||0.47% $14.0m|
|Independent Director||8.4yrs||US$485.32k||0.0045% $133.4k|
|Independent Director||8.4yrs||US$487.82k||0.042% $1.2m|
|Independent Director||3.8yrs||US$470.32k||no data|
|Independent Director||6.8yrs||US$477.82k||0.0027% $80.2k|
|Independent Director||8.4yrs||US$477.82k||0.0010% $29.7k|
|Lead Independent Director||7.5yrs||US$502.82k||0.0095% $279.5k|
|Independent Director||0.4yrs||no data||no data|
|Independent Director||0.4yrs||no data||no data|
Experienced Board: 8AK's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 8AK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alkermes plc's company bio, employee growth, exchange listings and data sources
- Name: Alkermes plc
- Ticker: 8AK
- Exchange: DB
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.197b
- Listing Market Cap: US$2.939b
- Shares outstanding: 157.79m
- Website: https://www.alkermes.com
Number of Employees
- Alkermes plc
- Connaught House
- 1 Burlington Road
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALKS||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Jul 1991|
|8AK||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jul 1991|
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 23:27|
|End of Day Share Price||2019/12/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.